O
OrbiMed Portfolio holdings
AUM
$5.4B
Turnover
40.13%
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+30.69%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.46B
AUM Growth
+$453M
(+9%)
Cap. Flow
-$312M
Cap. Flow
% of AUM
-5.72%
Top 10 Holdings %
Top 10 Hldgs %
38.94%
Holding
132
New
22
Increased
22
Reduced
29
Closed
18
Avg Time Held Equity + Options
2.6
years
Top 10 Avg Time Held Equity + Options
0.9
years
Top 20 Avg Time Held Equity + Options
1.3
years
Avg Time Held Equity only
2.6
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ArriVent BioPharma
AVBP
|
+$61.1M |
| 2 |
Cytokinetics
CYTK
|
+$52.8M |
| 3 |
Esperion Therapeutics
ESPR
|
+$33.3M |
| 4 |
Merck
MRK
|
+$32.2M |
| 5 |
Q32 Bio
QTTB
|
+$31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RayzeBio, Inc. Common Stock
RYZB
|
+$147M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$93.5M |
| 3 |
United Therapeutics
UTHR
|
+$84.9M |
| 4 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
+$71.7M |
| 5 |
SpringWorks Therapeutics
SWTX
|
+$69.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.1% |
| 2 | Miscellaneous | 0.9% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Praxis Precision Medicines
PRAX
$6.67B
| $28.1M | 0.51% |
+460,512
| New | +$20.7M |
2024 Q1
0 quarters
|
|
52
Heron Therapeutics
HRTX
$68.7M
| $28M | 0.51% |
10,111,550
+4,182,959
| +71% | +$10.5M |
2023 Q1
4 quarters
|
|
53
DELISTED
scPharmaceuticals
SCPH
| $27.9M | 0.51% |
5,559,528
| – | – |
2017 Q4
25 quarters
|
|
54
DELISTED
ACELYRIN
SLRN
| $27M | 0.49% |
4,001,711
| – | – |
2023 Q2
3 quarters
|
|
55
Adicet Bio
ACET
$45.8M
| $26.9M | 0.49% |
715,446
+195,312
| +38% | +$8.08M |
2018 Q1
24 quarters
|
|
56
Mineralys Therapeutics
MLYS
$1.84B
| $26.1M | 0.48% |
+2,021,424
| New | +$25M |
2024 Q1
0 quarters
|
|
|
RNAM
57
DELISTED
Avidity Biosciences
RNAM
| $25.4M | 0.46% |
+994,100
| New | +$15.6M |
2024 Q1
0 quarters
|
|
58
Xenon Pharmaceuticals
XENE
$3.28B
| $23.7M | 0.43% |
550,000
| – | – |
2016 Q3
30 quarters
|
|
59
Regeneron Pharmaceuticals
REGN
$80.1B
| $21.9M | 0.4% |
22,800
+9,300
| +69% | +$8.84M |
2023 Q1
4 quarters
|
|
|
KNTE
60
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $21.3M | 0.39% |
8,009,729
| – | – |
2020 Q4
13 quarters
|
|
61
Arrowhead Research
ARWR
$8.25B
| $21.2M | 0.39% |
739,651
+420,000
| +131% | +$13.4M |
2023 Q2
3 quarters
|
|
62
Neumora Therapeutics
NMRA
$66.6M
| $20.6M | 0.38% |
1,500,000
| – | – |
2023 Q3
2 quarters
|
|
63
Dyne Therapeutics
DYN
$2.81B
| $20.1M | 0.37% |
+708,400
| New | +$16M |
2024 Q1
0 quarters
|
|
64
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $19.7M | 0.36% |
558,500
+285,100
| +104% | +$9.56M |
2023 Q2
3 quarters
|
|
65
DexCom
DXCM
$31.5B
| $19.5M | 0.36% |
140,300
+67,100
| +92% | +$8.43M |
2023 Q4
1 quarter
|
|
66
AbCellera Biologics
ABCL
$4.01B
| $18.9M | 0.35% |
4,180,768
| – | – |
2020 Q4
13 quarters
|
|
67
Immatics
IMTX
$1.07B
| $18.6M | 0.34% |
1,769,708
+226,301
| +15% | +$2.64M |
2023 Q1
4 quarters
|
|
68
Verastem
VSTM
$698M
| $18M | 0.33% |
1,529,115
| – | – |
2022 Q3
6 quarters
|
|
69
Amgen
AMGN
$230B
| $18M | 0.33% |
63,400
-63,900
| -50% | -$18.7M |
2023 Q1
4 quarters
|
|
70
Jade Biosciences
JBIO
$855M
| $16.7M | 0.31% |
16,154
-5,473
| -25% | -$4.18M |
2021 Q2
11 quarters
|
|
71
TELA Bio
TELA
$49.2M
| $16.1M | 0.29% |
2,835,542
| – | – |
2019 Q4
17 quarters
|
|
72
DELISTED
Repare Therapeutics
RPTX
| $15.6M | 0.29% |
3,322,488
| – | – |
2020 Q2
15 quarters
|
|
73
Passage Bio
PASG
$11.8M
| $13.7M | 0.25% |
506,229
| – | – |
2020 Q1
16 quarters
|
|
74
Tyra Biosciences
TYRA
$1.29B
| $12.6M | 0.23% |
+768,638
| New | +$12.6M |
2024 Q1
0 quarters
|
|
75
Corvus Pharmaceuticals
CRVS
$789M
| $12.4M | 0.23% |
6,943,654
| – | – |
2016 Q1
32 quarters
|
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q1 2024 Portfolio in Review
As of Q1 2024, OrbiMed held 132 positions worth $5.46B, up 9% from $5.01B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
OrbiMed withdrew a net $312M in Q1 2024, closing 18 positions and reducing 29 holdings. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $147M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, OrbiMed opened a new position in ArriVent BioPharma worth $54.1M.
- OrbiMed's largest Q1 2024 buy was ArriVent BioPharma: 3,027,328 shares worth $54.1M.
- OrbiMed added most to Merck in Q1 2024, an estimated $32.2M increase.
- OrbiMed's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $69.9M.
- OrbiMed fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $147M.
- OrbiMed's ten largest holdings make up 39% of its $5.46B portfolio in Q1 2024.
- OrbiMed opened 22 new positions and closed 18 in Q1 2024.
- OrbiMed's portfolio value rose 9% quarter-over-quarter to $5.46B.
Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.